All posts by : Matteo Balocco

SAN FRANCISCO, CA – September 30, 2025– Multiply Labs, a San Francisco-based robotics company developing advanced automated manufacturing systems for cell therapies, today announced an expansion of its collaboration with Thermo Fisher Scientific, the world leader in serving science. The enhanced collaboration will focus on integrating Thermo Fisher’s automated Gibco™ CTS™ DynaCellect™ Magnetic Separation System with Multiply Labs’ state-of-the-art robotic platforms. 

The Gibco™ CTS™ DynaCellect™ System is a closed, automated isolation, activation and bead removal system for cell therapy development and manufacturing. Together with fit-for-purpose consumables, it offers high cell purity, recovery and viability. By combining the Gibco™ CTS™ DynaCellect™ System with Multiply Labs’ robotic automation expertise, the collaboration will accelerate critical steps in cell therapy production by reducing manual intervention and improving process consistency.

“Thermo Fisher is committed to advancing cell therapy manufacturing through innovative, scalable solutions,” said Andy Campbell, senior director of research and development at Thermo Fisher Scientific. “Our expanded collaboration with Multiply Labs will enable customers to achieve end-to-end automation in their manufacturing processes, ultimately accelerating the delivery of transformative therapies to patients.”

Multiply Labs’ robotic systems are designed to automate complex biomanufacturing workflows, enabling high-throughput, flexible production of cell therapies. Integrating these capabilities with the Gibco™ CTS™ DynaCellect™ System will enhance customers’ ability to achieve seamless, end-to-end cell separation and processing.

“We are excited about continuing to integrate leading, GMP-ready instruments with our robotic technology,” said Fred Parietti, PhD, Co-Founder and CEO of Multiply Labs. “This extended partnership is another step toward fully autonomous cell therapy manufacturing, reducing costs, minimizing human error, and ultimately getting treatments to patients faster.”

This collaboration builds on the companies’ existing collaboration, which has focused on automating cell expansion and separation processes, including the Heracell™ VIOS Automated Access CO2 Incubator and the Gibco™ CTS™ Rotea™ Counterflow Centrifugation System.

SAN FRANCISCO, CA – June 12, 2025 – Multiply Labs, a pioneering robotics company developing industry-leading automated manufacturing systems for advanced therapies, today announced a pilot collaboration with Kyverna Therapeutics (NASDAQ: KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases. 

Through this pilot, Kyverna will evaluate the automation of its cell therapy manufacturing processes using Multiply Labs’ robotic systems for KYV-102, a next-generation product candidate incorporating its patented fully human CD19 CAR T and proprietary whole-blood rapid manufacturing approach.

“This collaboration presents a unique opportunity to combine our deep expertise in manufacturing automation with Kyverna’s innovative work in cell therapy for autoimmune diseases,” said Fred Parietti, Ph.D., Co-founder and CEO of Multiply Labs. “Through our processes, we aim to reduce labor costs, increase manufacturing efficiency, and ultimately scale cell and gene therapies to reach more patients faster.”

Multiply Labs’ advanced robotic systems are designed to operate a wide range of industry-standard cell therapy manufacturing instruments seamlessly. This approach to manufacturing significantly reduces the need for process modifications, enabling a faster and more efficient transition to automated cell therapy production compared to traditional methods.

Multiply Labs recently pioneered the industry’s first study directly comparing the execution of critical cell therapy manufacturing steps by robots versus manual methods. The results demonstrated that robotic systems can achieve comparable accuracy and precision to the human operator while enabling end-to-end automation of the complete manufacturing processes.

This collaboration will further leverage Resonance, Multiply Labs’ robotic auto-training pipeline that enables robots to rapidly learn new processes directly from video demonstration data. Combining video auto-segmentation with automated trajectory extraction, Resonance streamlines the automation of complex biomanufacturing processes, enabling rapid deployment of robotic workflows at scale.